Comfyde Approval Status
Comfyde (carisbamate) is an investigational neuromodulatory agent intended for use as an adjunctive treatment of partial onset seizures.
In August 2009, Ortho-McNeil-Janssen Pharmaceuticals, Inc. announced the receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA), advising the companies that the New Drug Application (NDA) for Comfyde (carisbamate) had not been approved.
Development Status and FDA Approval Process for Comfyde
|Aug 25, 2009||FDA Issues Complete Response Letter for Carisbamate|
|Oct 24, 2008||Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Submits New Drug Application to FDA for Carisbamate|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.